Fibrobiologics

IN THE PRESS

Press Releases

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 26, 2026

·

3 min read

Press Releases

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

March 12, 2026

·

5 min read

Press Releases

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

March 5, 2026

·

5 min read

Press Releases

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

March 2, 2026

·

5 min read

Press Releases

FibroBiologics to Present at the BIO Investment & Growth Summit 2026

February 26, 2026

·

1 min read

Press Releases

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

·

7 min read

Press Releases

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

February 23, 2026

·

4 min read

Press Releases

FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

February 10, 2026

·

3 min read

Press Releases

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

February 5, 2026

·

4 min read

Press Releases

FibroBiologics to Present at the DealFlow Discovery Conference

January 20, 2026

·

1 min read

JOBS